Journal of Clinical Oncology, Vol 16, 453-461, Copyright © 1998 by American Society of Clinical Oncology

ARTICLES

Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate

P Dombernowsky, I Smith, G Falkson, R Leonard, L Panasci, J Bellmunt, W Bezwoda, G Gardin, A Gudgeon, M Morgan, A Fornasiero, W Hoffmann, J Michel, T Hatschek, T Tjabbes, HA Chaudri, U Hornberger and PF Trunet

PURPOSE: To compare two doses of letrozole and megestrol acetate (MA) as second-line therapy in postmenopausal women with advanced breast cancer previously treated with antiestrogens. PATIENTS AND METHODS: Five hundred fifty-one patients with locally advanced, locoregionally recurrent or metastatic breast cancer were randomly assigned to receive letrozole 2.5 mg (n = 174), letrozole 0.5 mg (n = 188), or MA 160 mg (n = 189) once daily in a double-blind, multicenter trial. Data were analyzed for tumor response and safety variables up to 33 months of follow-up evaluation and for survival up to 45 months. RESULTS: Letrozole 2.5 mg produced a significantly higher overall objective response rate (24%) compared with MA (16%; logistic regression, P = .04) or letrozole 0.5 mg (13%; P = .004). Duration of objective response was significantly longer for letrozole 2.5 mg compared with MA (Cox regression, P = .02). Letrozole 2.5 mg was significantly superior to MA and letrozole 0.5 mg in time to treatment failure (P = .04 and P = .002, respectively). For time to progression, letrozole 2.5 mg was superior to letrozole 0.5 mg (P = .02), but not to MA (P = .07). There was a significant dose effect in overall survival in favor of letrozole 2.5 mg (P = .03) compared with letrozole 0.5 mg. Letrozole was significantly better tolerated than MA with respect to serious adverse experiences, discontinuation due to poor tolerability, cardiovascular side effects, and weight gain. CONCLUSION: The data show letrozole 2.5 mg once daily to be more effective and better tolerated than MA in the treatment of postmenopausal women with advanced breast cancer previously treated with antiestrogens.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				C. H. Barrios, C. Sampaio, J. Vinholes, and R. Caponero What is the role of chemotherapy in estrogen receptor-positive, advanced breast cancer? Ann. Onc., July 1, 2009; 20(7): 1157 - 1162. [Abstract] [Full Text] [PDF]

				V. Guarneri and P. Conte Metastatic Breast Cancer: Therapeutic Options According to Molecular Subtypes and Prior Adjuvant Therapy Oncologist, July 1, 2009; 14(7): 645 - 656. [Abstract] [Full Text] [PDF]

				G. K. Ellis, H. G. Bone, R. Chlebowski, D. Paul, S. Spadafora, J. Smith, M. Fan, and S. Jun Randomized Trial of Denosumab in Patients Receiving Adjuvant Aromatase Inhibitors for Nonmetastatic Breast Cancer J. Clin. Oncol., October 20, 2008; 26(30): 4875 - 4882. [Abstract] [Full Text] [PDF]

				R. E. Greene and V. Tsang Hormonal Therapy for the Treatment of Postmenopausal Breast Cancer Patients Journal of Pharmacy Practice, February 1, 2008; 21(1): 36 - 45. [Abstract] [PDF]

				M. Colozza, E. de Azambuja, N. Personeni, F. Lebrun, M. J. Piccart, and F. Cardoso Achievements in Systemic Therapies in the Pregenomic Era in Metastatic Breast Cancer Oncologist, March 1, 2007; 12(3): 253 - 270. [Abstract] [Full Text] [PDF]

				S Beslija, J Bonneterre, H Burstein, V Cocquyt, M Gnant, P Goodwin, V Heinemann, J Jassem, W. Kostler, M Krainer, et al. Second consensus on medical treatment of metastatic breast cancer Ann. Onc., February 1, 2007; 18(2): 215 - 225. [Abstract] [Full Text] [PDF]

				D. Mauri, N. Pavlidis, N. P. Polyzos, and J. P. A. Ioannidis Survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer: meta-analysis. J Natl Cancer Inst, September 20, 2006; 98(18): 1285 - 1291. [Abstract] [Full Text] [PDF]

				R. J. Pietras Biologic Basis of Sequential and Combination Therapies for Hormone-Responsive Breast Cancer Oncologist, July 1, 2006; 11(7): 704 - 717. [Abstract] [Full Text] [PDF]

				K. Altundag and N. K. Ibrahim Aromatase inhibitors in breast cancer: an overview. Oncologist, June 1, 2006; 11(6): 553 - 562. [Abstract] [Full Text] [PDF]

				M. Neyt, J. Albrecht, and V. Cocquyt An economic evaluation of Herceptin(R) in adjuvant setting: the Breast Cancer International Research Group 006 trial Ann. Onc., March 1, 2006; 17(3): 381 - 390. [Abstract] [Full Text] [PDF]

				I. Vergote and P. Abram Fulvestrant, a new treatment option for advanced breast cancer: tolerability versus existing agents Ann. Onc., February 1, 2006; 17(2): 200 - 204. [Abstract] [Full Text] [PDF]

				N. Normanno, M. Di Maio, E. De Maio, A. De Luca, A. de Matteis, A. Giordano, F. Perrone, and on behalf of the NCI-Naples Breast Cancer Group Mechanisms of endocrine resistance and novel therapeutic strategies in breast cancer Endocr. Relat. Cancer, December 1, 2005; 12(4): 721 - 747. [Abstract] [Full Text] [PDF]

				L-A Martin, S Pancholi, C M W Chan, I Farmer, C Kimberley, M Dowsett, and S R D Johnston The anti-oestrogen ICI 182,780, but not tamoxifen, inhibits the growth of MCF-7 breast cancer cells refractory to long-term oestrogen deprivation through down-regulation of oestrogen receptor and IGF signalling Endocr. Relat. Cancer, December 1, 2005; 12(4): 1017 - 1036. [Abstract] [Full Text] [PDF]

				H. Gogas, C. Markopoulos, and R. Blamey Should women be advised to take prophylactic endocrine treatment outside of a clinical trial setting? Ann. Onc., December 1, 2005; 16(12): 1861 - 1866. [Abstract] [Full Text] [PDF]

				T. J. Whelan, P. E. Goss, J. N. Ingle, J. L. Pater, D. Tu, K. Pritchard, S. Liu, L. E. Shepherd, M. Palmer, N. J. Robert, et al. Assessment of Quality of Life in MA.17: A Randomized, Placebo-Controlled Trial of Letrozole After 5 Years of Tamoxifen in Postmenopausal Women J. Clin. Oncol., October 1, 2005; 23(28): 6931 - 6940. [Abstract] [Full Text] [PDF]

				A. Boulay, J. Rudloff, J. Ye, S. Zumstein-Mecker, T. O'Reilly, D. B. Evans, S. Chen, and H. A. Lane Dual Inhibition of mTOR and Estrogen Receptor Signaling In vitro Induces Cell Death in Models of Breast Cancer Clin. Cancer Res., July 15, 2005; 11(14): 5319 - 5328. [Abstract] [Full Text] [PDF]

				A. Howell and A. M Wardley Overview of the impact of conventional systemic therapies on breast cancer Endocr. Relat. Cancer, July 1, 2005; 12(Supplement_1): S9 - S16. [Abstract] [Full Text] [PDF]

				R. W. Brueggemeier, J. C. Hackett, and E. S. Diaz-Cruz Aromatase Inhibitors in the Treatment of Breast Cancer Endocr. Rev., May 1, 2005; 26(3): 331 - 345. [Abstract] [Full Text] [PDF]

				R. Kudachadkar and R. M. O'Regan Aromatase Inhibitors as Adjuvant Therapy for Postmenopausal Patients With Early Stage Breast Cancer CA Cancer J Clin, May 1, 2005; 55(3): 145 - 163. [Abstract] [Full Text] [PDF]

				J. Cuzick Aromatase Inhibitors for Breast Cancer Prevention J. Clin. Oncol., March 10, 2005; 23(8): 1636 - 1643. [Full Text] [PDF]

				K. Strasser-Weippl and P. E. Goss Advances in Adjuvant Hormonal Therapy for Postmenopausal Women J. Clin. Oncol., March 10, 2005; 23(8): 1751 - 1759. [Full Text] [PDF]

				R. R. Love, P. R. Hutson, T. C. Havighurst, and J. F. Cleary Endocrine Effects of Tamoxifen Plus Exemestane in Postmenopausal Women with Breast Cancer Clin. Cancer Res., February 15, 2005; 11(4): 1500 - 1503. [Abstract] [Full Text] [PDF]

				J. S. Tobias Recent advances in endocrine therapy for postmenopausal women with early breast cancer: implications for treatment and prevention Ann. Onc., December 1, 2004; 15(12): 1738 - 1747. [Abstract] [Full Text] [PDF]

				C. Bernard-Marty, F. Cardoso, and M. J. Piccart Facts and Controversies in Systemic Treatment of Metastatic Breast Cancer Oncologist, November 1, 2004; 9(6): 617 - 632. [Abstract] [Full Text] [PDF]

				N Angelopoulos, V Barbounis, S Livadas, D Kaltsas, and G Tolis Effects of estrogen deprivation due to breast cancer treatment Endocr. Relat. Cancer, September 1, 2004; 11(3): 523 - 535. [Abstract] [Full Text] [PDF]

				H. Mouridsen, Y. Sun, M. Gershanovich, R. Perez-Carrion, D. Becquart, H.A. Chaudri-Ross, and R. Lang Superiority of Letrozole to Tamoxifen in the First-Line Treatment of Advanced Breast Cancer: Evidence from Metastatic Subgroups and a Test of Functional Ability Oncologist, September 1, 2004; 9(5): 489 - 496. [Abstract] [Full Text] [PDF]

				F. Andre, K. Slimane, T. Bachelot, A. Dunant, M. Namer, A. Barrelier, O. Kabbaj, J. P. Spano, H. Marsiglia, R. Rouzier, et al. Breast Cancer With Synchronous Metastases: Trends in Survival During a 14-Year Period J. Clin. Oncol., August 15, 2004; 22(16): 3302 - 3308. [Abstract] [Full Text] [PDF]

				W. J. Gradishar Tamoxifen--What Next? Oncologist, July 1, 2004; 9(4): 378 - 384. [Abstract] [Full Text] [PDF]

				M. Ellis Overcoming Endocrine Therapy Resistance by Signal Transduction Inhibition Oncologist, June 3, 2004; 9(suppl_3): 20 - 26. [Abstract] [Full Text] [PDF]

				S. M. Campos Aromatase Inhibitors for Breast Cancer in Postmenopausal Women Oncologist, April 1, 2004; 9(2): 126 - 136. [Abstract] [Full Text] [PDF]

				B. J. Long, D. Jelovac, V. Handratta, A. Thiantanawat, N. MacPherson, J. Ragaz, O. G. Goloubeva, and A. M. Brodie Therapeutic Strategies Using the Aromatase Inhibitor Letrozole and Tamoxifen in a Breast Cancer Model J Natl Cancer Inst, March 17, 2004; 96(6): 456 - 465. [Abstract] [Full Text] [PDF]

				R. C. Coombes, E. Hall, L. J. Gibson, R. Paridaens, J. Jassem, T. Delozier, S. E. Jones, I. Alvarez, G. Bertelli, O. Ortmann, et al. A Randomized Trial of Exemestane after Two to Three Years of Tamoxifen Therapy in Postmenopausal Women with Primary Breast Cancer N. Engl. J. Med., March 11, 2004; 350(11): 1081 - 1092. [Abstract] [Full Text] [PDF]

				M. J. Ellis, A. Coop, B. Singh, Y. Tao, A. Llombart-Cussac, F. Janicke, L. Mauriac, E. Quebe-Fehling, H. A. Chaudri-Ross, D. B. Evans, et al. Letrozole Inhibits Tumor Proliferation More Effectively than Tamoxifen Independent of HER1/2 Expression Status Cancer Res., October 1, 2003; 63(19): 6523 - 6531. [Abstract] [Full Text] [PDF]

				E. P. Mamounas NSABP Breast Cancer Clinical Trials: Recent Results and Future Directions Clin. Med. Res., October 1, 2003; 1(4): 309 - 326. [Abstract] [Full Text] [PDF]

				R. Paridaens, L. Dirix, C. Lohrisch, L. Beex, M. Nooij, D. Cameron, L. Biganzoli, T. Cufer, L. Duchateau, A. Hamilton, et al. Mature results of a randomized phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer Ann. Onc., September 1, 2003; 14(9): 1391 - 1398. [Abstract] [Full Text] [PDF]

				M. Waeber, M. Castiglione-Gertsch, D. Dietrich, B. Thurlimann, A. Goldhirsch, K. W. Brunner, and M. M. Borner Adjuvant therapy after excision and radiation of isolated postmastectomy locoregional breast cancer recurrence: definitive results of a phase III randomized trial (SAKK 23/82) comparing tamoxifen with observation Ann. Onc., August 1, 2003; 14(8): 1215 - 1221. [Abstract] [Full Text] [PDF]

				A. U. Buzdar Advances in Endocrine Treatments for Postmenopausal Women with Metastatic and Early Breast Cancer Oncologist, August 1, 2003; 8(4): 335 - 341. [Abstract] [Full Text] [PDF]

				M. Piccart, L. M. Parker, and K. I. Pritchard Oestrogen receptor downregulation: an opportunity for extending the window of endocrine therapy in advanced breast cancer Ann. Onc., July 1, 2003; 14(7): 1017 - 1025. [Abstract] [Full Text] [PDF]

				I. E. Smith and M. Dowsett Aromatase Inhibitors in Breast Cancer N. Engl. J. Med., June 12, 2003; 348(24): 2431 - 2442. [Full Text] [PDF]

				H. Mouridsen, M. Gershanovich, Y. Sun, R. Perez-Carrion, C. Boni, A. Monnier, J. Apffelstaedt, R. Smith, H. P. Sleeboom, F. Jaenicke, et al. Phase III Study of Letrozole Versus Tamoxifen as First-Line Therapy of Advanced Breast Cancer in Postmenopausal Women: Analysis of Survival and Update of Efficacy From the International Letrozole Breast Cancer Group J. Clin. Oncol., June 1, 2003; 21(11): 2101 - 2109. [Abstract] [Full Text] [PDF]

				V. Valero and G. N. Hortobagyi Are Anthracycline-Taxane Regimens the New Standard of Care in the Treatment of Metastatic Breast Cancer? J. Clin. Oncol., March 15, 2003; 21(6): 959 - 962. [Full Text] [PDF]

				F. J. Esteva, J. Glaspy, S. Baidas, L. Laufman, L. Hutchins, M. Dickler, D. Tripathy, R. Cohen, A. DeMichele, R. C. Yocum, et al. Multicenter Phase II Study of Oral Bexarotene for Patients With Metastatic Breast Cancer J. Clin. Oncol., March 15, 2003; 21(6): 999 - 1006. [Abstract] [Full Text] [PDF]

				T. Tominaga, I. Adachi, Y. Sasaki, T. Tabei, T. Ikeda, Y. Takatsuka, M. Toi, T. Suwa, and Y. Ohashi Double-blind randomised trial comparing the non-steroidal aromatase inhibitors letrozole and fadrozole in postmenopausal women with advanced breast cancer Ann. Onc., January 1, 2003; 14(1): 62 - 70. [Abstract] [Full Text] [PDF]

				K. I. Pritchard Endocrine Therapy of Advanced Disease: Analysis and Implications of the Existing Data Clin. Cancer Res., January 1, 2003; 9(1): 460s - 467s. [Abstract] [Full Text]

				A. U. Buzdar Pharmacology and Pharmacokinetics of the Newer Generation Aromatase Inhibitors Clin. Cancer Res., January 1, 2003; 9(1): 468s - 472s. [Abstract] [Full Text]

				J. A. Ligibel and E. P. Winer Clinical Differences among the Aromatase Inhibitors Clin. Cancer Res., January 1, 2003; 9(1): 473s - 479s. [Abstract] [Full Text]

				I. C. Henderson A Rose Is No Longer a Rose J. Clin. Oncol., August 15, 2002; 20(16): 3365 - 3368. [Full Text] [PDF]

				E. P. Winer, C. Hudis, H. J. Burstein, R. T. Chlebowski, J. N. Ingle, S. B. Edge, E. P. Mamounas, J. Gralow, L. J. Goldstein, K. I. Pritchard, et al. American Society of Clinical Oncology Technology Assessment on the Use of Aromatase Inhibitors as Adjuvant Therapy for Women With Hormone Receptor-Positive Breast Cancer: Status Report 2002 J. Clin. Oncol., August 1, 2002; 20(15): 3317 - 3327. [Abstract] [Full Text] [PDF]

				E. Bajetta, A. Martinetti, N. Zilembo, P. Pozzi, I. La Torre, L. Ferrari, E. Seregni, R. Longarini, G. Salvucci, and E. Bombardieri Biological activity of anastrozole in postmenopausal patients with advanced breast cancer: effects on estrogens and bone metabolism Ann. Onc., July 1, 2002; 13(7): 1059 - 1066. [Abstract] [Full Text] [PDF]

				B. J. Long, D. Jelovac, A. Thiantanawat, and A. M. Brodie The Effect of Second-Line Antiestrogen Therapy on Breast Tumor Growth after First-Line Treatment with the Aromatase Inhibitor Letrozole: Long-Term Studies Using the Intratumoral Aromatase Postmenopausal Breast Cancer Model Clin. Cancer Res., July 1, 2002; 8(7): 2378 - 2388. [Abstract] [Full Text] [PDF]

				M. H. Cohen, J. R. Johnson, N. Li, G. Chen, and R. Pazdur Approval Summary: Letrozole in the Treatment of Postmenopausal Women with Advanced Breast Cancer Clin. Cancer Res., March 1, 2002; 8(3): 665 - 669. [Abstract] [Full Text] [PDF]

				R. M. O'Regan, C. Gajdos, R. C. Dardes, A. De Los Reyes, W. Park, A. W. Rademaker, and V. C. Jordan Effects of Raloxifene After Tamoxifen on Breast and Endometrial Tumor Growth in Athymic Mice J Natl Cancer Inst, February 20, 2002; 94(4): 274 - 283. [Abstract] [Full Text] [PDF]

				J. Geisler, B. Haynes, G. Anker, M. Dowsett, and P. E. Lonning Influence of Letrozole and Anastrozole on Total Body Aromatization and Plasma Estrogen Levels in Postmenopausal Breast Cancer Patients Evaluated in a Randomized, Cross-Over Study J. Clin. Oncol., February 1, 2002; 20(3): 751 - 757. [Abstract] [Full Text] [PDF]

				A. U. Buzdar, H. Mouridsen, and H. A. Chaudri-Ross Superior Efficacy of Letrozole Versus Tamoxifen as First-Line Therapy J. Clin. Oncol., February 1, 2002; 20(3): 876 - 878. [Full Text] [PDF]

				L. B. Michaud and K. L. Jones Recent Advances in the Systemic Management of Metastatic Breast Cancer Journal of Pharmacy Practice, February 1, 2002; 15(1): 52 - 61. [Abstract] [PDF]

				E. R. Simpson and M. Dowsett Aromatase and Its Inhibitors: Significance for Breast Cancer Therapy Recent Prog. Horm. Res., January 1, 2002; 57(1): 317 - 338. [Abstract] [Full Text] [PDF]

				G. Cocconi False Shortening of Time to Progression in Letrozole 2.5-mg Dose? J. Clin. Oncol., December 1, 2001; 19(23): 4353 - 4353. [Full Text]

				J. R. Mackey, A. A. Joy, A. U. Buzdar, C. Brady, and H. A. Chaudri-Ross Letrozole in Second-Line Therapy of Advanced Breast Cancer: More Questions Than Answers J. Clin. Oncol., December 1, 2001; 19(23): 4353 - 4355. [Full Text]

				F. Boccardo, A. Rubagotti, D. Amoroso, M. Mesiti, D. Romeo, C. Caroti, A. Farris, G. Cruciani, E. Villa, G. Schieppati, et al. Sequential Tamoxifen and Aminoglutethimide Versus Tamoxifen Alone in the Adjuvant Treatment of Postmenopausal Breast Cancer Patients: Results of an Italian Cooperative Study J. Clin. Oncol., November 15, 2001; 19(22): 4209 - 4215. [Abstract] [Full Text]

				P. E. Lonning Aromatase inhibitors and inactivators in breast cancer BMJ, October 20, 2001; 323(7318): 880 - 881. [Full Text] [PDF]

				S. Wickman and L. Dunkel Inhibition of P450 Aromatase Enhances Gonadotropin Secretion in Early and Midpubertal Boys: Evidence for a Pituitary Site of Action of Endogenous E J. Clin. Endocrinol. Metab., October 1, 2001; 86(10): 4887 - 4894. [Abstract] [Full Text] [PDF]

				A. Buzdar and A. Howell Advances in Aromatase Inhibition: Clinical Efficacy and Tolerability in the Treatment of Breast Cancer Clin. Cancer Res., September 1, 2001; 7(9): 2620 - 2635. [Full Text] [PDF]

				A. Buzdar, J. Douma, N. Davidson, R. Elledge, M. Morgan, R. Smith, L. Porter, J. Nabholtz, X. Xiang, and C. Brady Phase III, Multicenter, Double-Blind, Randomized Study of Letrozole, an Aromatase Inhibitor, for Advanced Breast Cancer Versus Megestrol Acetate J. Clin. Oncol., July 15, 2001; 19(14): 3357 - 3366. [Abstract] [Full Text] [PDF]

				H. Mouridsen, M. Gershanovich, Y. Sun, R. Perez-Carrion, C. Boni, A. Monnier, J. Apffelstaedt, R. Smith, H. P. Sleeboom, F. Janicke, et al. Superior Efficacy of Letrozole Versus Tamoxifen as First-Line Therapy for Postmenopausal Women With Advanced Breast Cancer: Results of a Phase III Study of the International Letrozole Breast Cancer Group J. Clin. Oncol., May 15, 2001; 19(10): 2596 - 2606. [Abstract] [Full Text] [PDF]

				P. P. Donnellan, S. L. Douglas, D. A. Cameron, and R. C.F. Leonard Aromatase Inhibitors and Arthralgia J. Clin. Oncol., May 15, 2001; 19(10): 2767 - 2767. [Full Text] [PDF]

				J. M. Nabholtz, J. Bonneterre, A. Buzdar, J. F.R. Robertson, B. Thurlimann, M. Steinberg, A. Webster, and M. von Euler Is Anastrozole Superior to Tamoxifen as First-Line Therapy for Advanced Breast Cancer?: In Reply J. Clin. Oncol., May 1, 2001; 19(9): 2580 - 2582. [Full Text] [PDF]

				J. Geisler, S. Detre, H. Berntsen, L. Ottestad, B. Lindtjørn, M. Dowsett, and P. E. Lønning Influence of Neoadjuvant Anastrozole (Arimidex) on Intratumoral Estrogen Levels and Proliferation Markers in Patients with Locally Advanced Breast Cancer Clin. Cancer Res., May 1, 2001; 7(5): 1230 - 1236. [Abstract] [Full Text]

				P. E. Goss and K. Strasser Aromatase Inhibitors in the Treatment and Prevention of Breast Cancer J. Clin. Oncol., February 1, 2001; 19(3): 881 - 894. [Abstract] [Full Text] [PDF]

				J. Bonneterre, B. Thurlimann, J. F. R. Robertson, M. Krzakowski, L. Mauriac, P. Koralewski, I. Vergote, A. Webster, M. Steinberg, and M. von Euler Anastrozole Versus Tamoxifen as First-Line Therapy for Advanced Breast Cancer in 668 Postmenopausal Women: Results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability Study J. Clin. Oncol., November 15, 2000; 18(22): 3748 - 3757. [Abstract] [Full Text] [PDF]

				J. M. Nabholtz, A. Buzdar, M. Pollak, W. Harwin, G. Burton, A. Mangalik, M. Steinberg, A. Webster, and M. von Euler Anastrozole Is Superior to Tamoxifen as First-Line Therapy for Advanced Breast Cancer in Postmenopausal Women: Results of a North American Multicenter Randomized Trial J. Clin. Oncol., November 15, 2000; 18(22): 3758 - 3767. [Abstract] [Full Text] [PDF]

				P. E. Lonning, E. Bajetta, R. Murray, M. Tubiana-Hulin, P. D. Eisenberg, E. Mickiewicz, L. Celio, P. Pitt, M. Mita, N. K. Aaronson, et al. Activity of Exemestane in Metastatic Breast Cancer After Failure of Nonsteroidal Aromatase Inhibitors: A Phase II Trial J. Clin. Oncol., June 11, 2000; 18(11): 2234 - 2244. [Abstract] [Full Text] [PDF]

				M. Kaufmann, E. Bajetta, L. Y. Dirix, L. E. Fein, S. E. Jones, N. Zilembo, J.-L. Dugardyn, C. Nasurdi, R. G. Mennel, J. Cervek, et al. Exemestane Is Superior to Megestrol Acetate After Tamoxifen Failure in Postmenopausal Women With Advanced Breast Cancer: Results of a Phase III Randomized Double-Blind Trial J. Clin. Oncol., April 7, 2000; 18(7): 1399 - 1411. [Abstract] [Full Text] [PDF]

				A. U. Buzdar, H. A. Chaudri, and P. F. Trunet Letrozole: Which Dose to Be Used? J. Clin. Oncol., April 1, 2000; 18(8): 1802 - 1803. [Full Text] [PDF]

				H. A. Chaudri and P. F. Trunet Letrozole: Updated Duration of Response J. Clin. Oncol., December 1, 1999; 17(12): 3856 - 3860. [Full Text] [PDF]

				S. Jones, C. Vogel, A. Arkhipov, L. Fehrenbacher, P. Eisenberg, B. Cooper, S. Honig, A. Polli, F. Whaley, E. di Salle, et al. Multicenter, Phase II Trial of Exemestane as Third-Line Hormonal Therapy of Postmenopausal Women With Metastatic Breast Cancer J. Clin. Oncol., November 1, 1999; 17(11): 3418 - 3425. [Abstract] [Full Text] [PDF]

				M. Dowsett, C. Pfister, S. R. D. Johnston, D. W. Miles, S. J. Houston, J. A. Verbeek, H. Gundacker, A. Sioufi, and I. E. Smith Impact of Tamoxifen on the Pharmacokinetics and Endocrine Effects of the Aromatase Inhibitor Letrozole in Postmenopausal Women with Breast Cancer Clin. Cancer Res., September 1, 1999; 5(9): 2338 - 2343. [Abstract] [Full Text] [PDF]

				J. N. Ingle, V. J. Suman, P. A. Johnson, J. E. Krook, J. A. Mailliard, R. H. Wheeler, C. L. Loprinzi, E. A. Perez, V. C. Jordan, and M. Dowsett Evaluation of Tamoxifen plus Letrozole with Assessment of Pharmacokinetic Interaction in Postmenopausal Women with Metastatic Breast Cancer Clin. Cancer Res., July 1, 1999; 5(7): 1642 - 1649. [Abstract] [Full Text] [PDF]

				G. B. Anker, H. Refsum, P. M. Ueland, D. C. Johannessen, E. A. Lien, and P. E. Lonning Influence of Aromatase Inhibitors on Plasma Total Homocysteine in Postmenopausal Breast Cancer Patients Clin. Chem., February 1, 1999; 45(2): 252 - 256. [Abstract] [Full Text] [PDF]

				P. E. Goss, E. P. Winer, I. F. Tannock, and L. H. Schwartz on behalf of the North American Vorozole Randomized Phase III Trial Comparing the New Potent and Selective Third-Generation Aromatase Inhibitor Vorozole With Megestrol Acetate in Postmenopausal Advanced Breast Cancer Patients J. Clin. Oncol., January 1, 1999; 17(1): 52 - 52. [Abstract] [Full Text] [PDF]